ClinicalTrials.gg
CompletedNCT01478581Updated Mar 10, 2020Results posted

Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma

A Phase 2 interventional study of PCI-32765 and Dexamethasone in Multiple Myeloma, sponsored by Pharmacyclics LLC.. Completed at 11 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-10.

Sponsored by Pharmacyclics LLC. (part of AbbVie) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
92
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 40 studies in Multiple Myeloma by AbbVie — 7 open to participants now, 17 under way, 5 of them phase 3. Multiple Myeloma · AbbVie.

Enrollment
19th of 39
92 · median 84
Started
2012
with 2 others
Phase 2
8 of 40
none open now
Registered
7th of 40
by date

Among the 40 studies in Multiple Myeloma by AbbVie, this one is the 19th largest by enrollment of the 39 interventional ones that give a count, is one of 3 that started in 2012, is one of 8 in phase 2, and was the 7th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

7 of the 40 studies in Multiple Myeloma by AbbVie are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 584 Multiple Myeloma studies recruiting now, 429 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Multiple Myeloma by AbbVie, or all of them as a file.
02

Study summary

The primary objective of this study is to determine the efficacy of PCI-32765, both as a single agent and in combination with dexamethasone, in subjects with relapsed or relapsed and refractory Multiple Myeloma (MM)

Read the detailed description

Bruton's tyrosine kinase (Btk) is an enzyme that is present in hematopoietic cells other than T cells and is necessary for downstream signal transduction from various hematopoietic receptors including the B cell receptor as well as some Fc, chemokine, and adhesion receptors, and is crucial for both B cell development and osteoclastogenesis. Although down-regulated in normal plasma cells, Btk is highly expressed in the malignant cells from many myeloma patients and some cell lines. PCI 32765 is a potent and specific inhibitor of Btk currently in Phase 2 clinical trials. The current study is designed and intended to determine the effects of PCI-32765 in subjects with MM.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • PCI-32765
  • Multiple Myeloma
  • Relapsed Refractory Multiple Myeloma
  • Bruton's Tyrosine Kinase
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of symptomatic MM with , defined here as having at least one of the following:

    1. Serum monoclonal protein (M-protein) ≥0.5 g/dL as determined by serum protein electrophoresis (SPEP)
    2. Urine M-protein ≥200 mg/24 hrs
    3. Serum free light chain (FLC) assay: involved FLC level ≥10 mg/dL (≥100 mg/L) provided serum FLC ratio is abnormal
  • or relapsed and refractory MM after receiving at least 2 but no more than 5 , 1 of which must be an immunomodulator.
  • Refractory myeloma (to most recent treatment) is defined as disease that is nonresponsive while on treatment or progressive disease within 60 days after the completion of preceding treatment. Nonresponsive disease is defined as either failure to achieve minimal response or development of progressive disease while on therapy.
  • Men and women ≥18 years of age.
  • performance status of ≤ 1.

Exclusion criteria

Exclusion Criteria:

  • Subject must not have primary disease defined as disease that is nonresponsive in subjects who have never achieved a minor response (MR) or better with any therapy.
  • Polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes (POEMS) syndrome, osteosclerotic myeloma, or Crow-Fukase syndrome.
  • Plasma cell leukemia.
  • Primary amyloidosis.
  • Certain exclusions on prior therapy.
  • ANC \<0.75 x 10\^9/L independent of growth factor support.
  • \<50 x 10\^9/L) independent of transfusion support.
  • or ALT ≥3.0 x (ULN).
  • Total >2.5 x ULN, unless due to Gilbert's syndrome.
  • Creatinine >2.5 mg/dL.
  • Unable to swallow capsules or disease significantly affecting gastrointestinal function.
  • Requires anti-coagulation with warfarin or a vitamin K antagonist. Requires treatment with strong /5 inhibitors.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
92 participants (actual)

Study arms

  • Experimental
    Cohort 1

    PCI-32765 420 mg per day

    Drug: PCI-32765

  • Experimental
    Cohort 2

    PCI-32765 560 mg per day, 40 mg dexamethasone (oral) once per week

    Drug: PCI-32765 · Drug: Dexamethasone

  • Experimental
    Cohort 3

    PCI-32765 840 mg per day

    Drug: PCI-32765

  • Experimental
    Cohort 4

    PCI-32765 840 mg per day, 40 mg dexamethasone (oral) once per week

    Drug: PCI-32765 · Drug: Dexamethasone

Interventions

06

What researchers measure

Primary outcomes

  1. The Clinical Benefit Response (CBR)

    The clinical benefit response (CBR) rate, defined as the proportion of subjects who achieved stringent complete response (sCR), complete response (CR), very good partial response (VGPR), partial response (PR), or minimal response (MR) as assessed by the modified International Myeloma Working Group (IMWG) response criteria

    Time frame: From the date of first study treatment until disease progression per IMWG, up to 60 months

Secondary outcomes

  1. To Evaluate the Efficacy of PCI-32765 by Assessing ORR

    The objective response rate, defined as the proportion of subjects who achieved stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR), as assessed by the modified International Myeloma Working Group (IMWG) response criteria.

    Time frame: From the date of first study treatment until disease progression per IMWG, up to 60 months

  2. Pharmacokinetics (PK). (Assessed by Sampling and Testing for Drug and Metabolite Levels at Designated Time Points). Mean Maximum Observed Plasma Concentration (Cmax)

    Ibrutinib and PCI-45227 concentrations were measurable following once-daily dosing of ibrutinib in subjects with MM. The following time-points were included: 0hr, 1hr, 2hr, 7hr, 24hr post-dose. Maximum observed plasma concentration of ibrutinib during the dosing interval on Day 8.

    Time frame: Procedure was performed up to 60 weeks.

  3. Pharmacokinetics (PK) (Assessed by Sampling and Testing for Drug and Metabolite Levels at Designated Time Points). Mean Time to Maximum Observed Plasma Concentration (Tmax).

    Ibrutinib and PCI-45227 concentrations were measurable following once-daily dosing of ibrutinib in subjects with MM. The following time-points were included: 0hr, 1hr, 2hr, 7hr, 24hr post-dose. Time to corresponding maximum observed plasma concentration of ibrutinib during the dosing interval on Day 8.

    Time frame: Procedure was performed up to 60 weeks.

  4. Pharmacokinetics (PK) (Assessed by Sampling and Testing for Drug and Metabolite Levels at Designated Time Points). Mean Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours (AUC0-24h).

    Ibrutinib and PCI-45227 concentrations were measurable following once-daily dosing of ibrutinib in subjects with MM. The following time-points were included: 0hr, 1hr, 2hr, 7hr, 24hr post-dose. Ibrutinib AUC0-24h calculated using linear trapezoidal summation after dosing from time 0 to 24 hours on Day 8.

    Time frame: Procedure was performed up to 60 weeks.

  5. Pharmacokinetics (PK) (Assessed by Sampling and Testing for Drug and Metabolite Levels at Designated Time Points). Mean Terminal Elimination Half-life (t1/2,Term).

    Ibrutinib and PCI-45227 concentrations were measurable following once-daily dosing of ibrutinib in subjects with MM. The following time-points were included: 0hr, 1hr, 2hr, 7hr, 24hr post-dose. Ibrutinib terminal elimination half-life associated with the terminal slope (λz) of the semi-logarithmic plasma concentration-time curve, calculated as 0.693/λz on Day 8.

    Time frame: Procedure was performed up to 60 weeks.

  6. Pharmacokinetics (PK) (Assessed by Sampling and Testing for Drug and Metabolite Levels at Designated Time Points). Mean Accumulation Ratio for AUC0-24h (Acc. Ratio AUC0-24h)

    Ibrutinib and PCI-45227 concentrations were measurable following once-daily dosing of ibrutinib in subjects with MM. The following time-points were included: 0hr, 1hr, 2hr, 7hr, 24hr post-dose. Acc. Ratio calculated as Day 8 ibrutinib AUC0-24h/ Day 1 ibrutinib AUC0-24h.

    Time frame: Procedure was performed up to 60 weeks.

  7. Pharmacokinetics (PK) (Assessed by Sampling and Testing for Drug and Metabolite Levels at Designated Time Points). Mean Metabolite-to-Parent Ratio for Cmax (M/P Cmax)

    Ibrutinib and PCI-45227 concentrations were measurable following once-daily dosing of ibrutinib in subjects with MM. The following time-points were included: 0hr, 1hr, 2hr, 7hr, 24hr post-dose. Calculated as (PCI-45227 Cmax/PCI-45227 molecular weight)/(ibrutinib Cmax/ibrutinib molecular weight) on Day 8.

    Time frame: Procedure was performed up to 60 weeks.

  8. Pharmacokinetics (PK) (Assessed by Sampling and Testing for Drug and Metabolite Levels at Designated Time Points). Mean Metabolite-to-Parent Ratio for AUC0-24h (M/P AUC0-24h)

    Ibrutinib and PCI-45227 concentrations were measurable following once-daily dosing of ibrutinib in subjects with MM. The following time-points were included: 0hr, 1hr, 2hr, 7hr, 24hr post-dose. Calculated as (PCI-45227 AUC0-24h/PCI-45227 molecular weight)/(ibrutinib AUC0-24h/ibrutinib molecular weight) on Day 8.

    Time frame: Procedure was performed up to 60 weeks.

  9. Duration of Clinical Benefit Response (DCB)

    DCB is defined as the time from first observation of response to the time of disease progression.

    Time frame: From the date of first study treatment until disease progression per IMWG, up to 60 months

  10. Duration of Response (DOR)

    The time interval between the date of initial documentation of a response and the date of first documented evidence of progressive disease, death, or date of censoring for the subjects not progressed/died. The censoring date is the last adequate tumor assessment date.

    Time frame: up to 3 Years

07

Results

Posted Jun 26, 2018

Participant flow

Participant flow — Overall Study
MilestonePCI-32765 420 mg Per DayPCI-32765 560 mg Per Day, 40 mg DexamethasonePCI-32765 840 mg Per DayPCI-32765 840 mg Per Day, 40 mg Dexamethasone
Started13181843
Completed13181843
Not completed0000

Outcome measures

PrimaryThe Clinical Benefit Response (CBR)

The clinical benefit response (CBR) rate, defined as the proportion of subjects who achieved stringent complete response (sCR), complete response (CR), very good partial response (VGPR), partial response (PR), or minimal response (MR) as assessed by the modified International Myeloma Working Group (IMWG) response criteria

Time frame:
From the date of first study treatment until disease progression per IMWG, up to 60 months
Reported as:
Count of participants · Participants
The Clinical Benefit Response (CBR)
ParticipantsCohort 1Cohort 2Cohort 3Cohort 4
The Clinical Benefit Response (CBR)11012
SecondaryTo Evaluate the Efficacy of PCI-32765 by Assessing ORR

The objective response rate, defined as the proportion of subjects who achieved stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR), as assessed by the modified International Myeloma Working Group (IMWG) response criteria.

Time frame:
From the date of first study treatment until disease progression per IMWG, up to 60 months
Reported as:
Count of participants · Participants
To Evaluate the Efficacy of PCI-32765 by Assessing ORR
ParticipantsCohort 1Cohort 2Cohort 3Cohort 4
To Evaluate the Efficacy of PCI-32765 by Assessing ORR0102
SecondaryPharmacokinetics (PK). (Assessed by Sampling and Testing for Drug and Metabolite Levels at Designated Time Points). Mean Maximum Observed Plasma Concentration (Cmax)

Ibrutinib and PCI-45227 concentrations were measurable following once-daily dosing of ibrutinib in subjects with MM. The following time-points were included: 0hr, 1hr, 2hr, 7hr, 24hr post-dose. Maximum observed plasma concentration of ibrutinib during the dosing interval on Day 8.

Time frame:
Procedure was performed up to 60 weeks.
Reported as:
Mean · ng/mL
Pharmacokinetics (PK). (Assessed by Sampling and Testing for Drug and Metabolite Levels at Designated Time Points). Mean Maximum Observed Plasma Concentration (Cmax)
ng/mLCohort 1Cohort 2Cohort 3Cohort 4
Pharmacokinetics (PK). (Assessed by Sampling and Testing for Drug and Metabolite Levels at Designated Time Points). Mean Maximum Observed Plasma Concentration (Cmax)157 ± 126103 ± 96.7219 ± 159166 ± 200
SecondaryPharmacokinetics (PK) (Assessed by Sampling and Testing for Drug and Metabolite Levels at Designated Time Points). Mean Time to Maximum Observed Plasma Concentration (Tmax).

Ibrutinib and PCI-45227 concentrations were measurable following once-daily dosing of ibrutinib in subjects with MM. The following time-points were included: 0hr, 1hr, 2hr, 7hr, 24hr post-dose. Time to corresponding maximum observed plasma concentration of ibrutinib during the dosing interval on Day 8.

Time frame:
Procedure was performed up to 60 weeks.
Reported as:
Mean · hours
Pharmacokinetics (PK) (Assessed by Sampling and Testing for Drug and Metabolite Levels at Designated Time Points). Mean Time to Maximum Observed Plasma Concentration (Tmax).
hoursCohort 1Cohort 2Cohort 3Cohort 4
Pharmacokinetics (PK) (Assessed by Sampling and Testing for Drug and Metabolite Levels at Designated Time Points). Mean Time to Maximum Observed Plasma Concentration (Tmax).2.73 ± 1.992.32 ± 1.721.95 ± 0.9442.25 ± 1.18
SecondaryPharmacokinetics (PK) (Assessed by Sampling and Testing for Drug and Metabolite Levels at Designated Time Points). Mean Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours (AUC0-24h).

Ibrutinib and PCI-45227 concentrations were measurable following once-daily dosing of ibrutinib in subjects with MM. The following time-points were included: 0hr, 1hr, 2hr, 7hr, 24hr post-dose. Ibrutinib AUC0-24h calculated using linear trapezoidal summation after dosing from time 0 to 24 hours on Day 8.

Time frame:
Procedure was performed up to 60 weeks.
Reported as:
Mean · h∙ng/mL
Pharmacokinetics (PK) (Assessed by Sampling and Testing for Drug and Metabolite Levels at Designated Time Points). Mean Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours (AUC0-24h).
h∙ng/mLCohort 1Cohort 2Cohort 3Cohort 4
Pharmacokinetics (PK) (Assessed by Sampling and Testing for Drug and Metabolite Levels at Designated Time Points). Mean Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours (AUC0-24h).1094 ± 808723 ± 7681423 ± 10141230 ± 1914
SecondaryPharmacokinetics (PK) (Assessed by Sampling and Testing for Drug and Metabolite Levels at Designated Time Points). Mean Terminal Elimination Half-life (t1/2,Term).

Ibrutinib and PCI-45227 concentrations were measurable following once-daily dosing of ibrutinib in subjects with MM. The following time-points were included: 0hr, 1hr, 2hr, 7hr, 24hr post-dose. Ibrutinib terminal elimination half-life associated with the terminal slope (λz) of the semi-logarithmic plasma concentration-time curve, calculated as 0.693/λz on Day 8.

Time frame:
Procedure was performed up to 60 weeks.
Reported as:
Mean · hours
Pharmacokinetics (PK) (Assessed by Sampling and Testing for Drug and Metabolite Levels at Designated Time Points). Mean Terminal Elimination Half-life (t1/2,Term).
hoursCohort 1Cohort 2Cohort 3Cohort 4
Pharmacokinetics (PK) (Assessed by Sampling and Testing for Drug and Metabolite Levels at Designated Time Points). Mean Terminal Elimination Half-life (t1/2,Term).7.76 ± 1.396.95 ± 0.8218.42 ± 2.856.90 ± 1.81
SecondaryPharmacokinetics (PK) (Assessed by Sampling and Testing for Drug and Metabolite Levels at Designated Time Points). Mean Accumulation Ratio for AUC0-24h (Acc. Ratio AUC0-24h)

Ibrutinib and PCI-45227 concentrations were measurable following once-daily dosing of ibrutinib in subjects with MM. The following time-points were included: 0hr, 1hr, 2hr, 7hr, 24hr post-dose. Acc. Ratio calculated as Day 8 ibrutinib AUC0-24h/ Day 1 ibrutinib AUC0-24h.

Time frame:
Procedure was performed up to 60 weeks.
Reported as:
Mean · Ratio
Pharmacokinetics (PK) (Assessed by Sampling and Testing for Drug and Metabolite Levels at Designated Time Points). Mean Accumulation Ratio for AUC0-24h (Acc. Ratio AUC0-24h)
RatioCohort 1Cohort 2Cohort 3Cohort 4
Pharmacokinetics (PK) (Assessed by Sampling and Testing for Drug and Metabolite Levels at Designated Time Points). Mean Accumulation Ratio for AUC0-24h (Acc. Ratio AUC0-24h)2.75 ± 3.361.90 ± 1.641.88 ± 1.411.31 ± 0.830
SecondaryPharmacokinetics (PK) (Assessed by Sampling and Testing for Drug and Metabolite Levels at Designated Time Points). Mean Metabolite-to-Parent Ratio for Cmax (M/P Cmax)

Ibrutinib and PCI-45227 concentrations were measurable following once-daily dosing of ibrutinib in subjects with MM. The following time-points were included: 0hr, 1hr, 2hr, 7hr, 24hr post-dose. Calculated as (PCI-45227 Cmax/PCI-45227 molecular weight)/(ibrutinib Cmax/ibrutinib molecular weight) on Day 8.

Time frame:
Procedure was performed up to 60 weeks.
Reported as:
Mean · Ratio
Pharmacokinetics (PK) (Assessed by Sampling and Testing for Drug and Metabolite Levels at Designated Time Points). Mean Metabolite-to-Parent Ratio for Cmax (M/P Cmax)
RatioCohort 1Cohort 2Cohort 3Cohort 4
Pharmacokinetics (PK) (Assessed by Sampling and Testing for Drug and Metabolite Levels at Designated Time Points). Mean Metabolite-to-Parent Ratio for Cmax (M/P Cmax)0.952 ± 0.4641.47 ± 0.6321.39 ± 1.361.39 ± 0.746
SecondaryPharmacokinetics (PK) (Assessed by Sampling and Testing for Drug and Metabolite Levels at Designated Time Points). Mean Metabolite-to-Parent Ratio for AUC0-24h (M/P AUC0-24h)

Ibrutinib and PCI-45227 concentrations were measurable following once-daily dosing of ibrutinib in subjects with MM. The following time-points were included: 0hr, 1hr, 2hr, 7hr, 24hr post-dose. Calculated as (PCI-45227 AUC0-24h/PCI-45227 molecular weight)/(ibrutinib AUC0-24h/ibrutinib molecular weight) on Day 8.

Time frame:
Procedure was performed up to 60 weeks.
Reported as:
Mean · Ratio
Pharmacokinetics (PK) (Assessed by Sampling and Testing for Drug and Metabolite Levels at Designated Time Points). Mean Metabolite-to-Parent Ratio for AUC0-24h (M/P AUC0-24h)
RatioCohort 1Cohort 2Cohort 3Cohort 4
Pharmacokinetics (PK) (Assessed by Sampling and Testing for Drug and Metabolite Levels at Designated Time Points). Mean Metabolite-to-Parent Ratio for AUC0-24h (M/P AUC0-24h)1.44 ± 0.5672.21 ± 0.9851.90 ± 1.351.96 ± 0.923
SecondaryDuration of Clinical Benefit Response (DCB)

DCB is defined as the time from first observation of response to the time of disease progression.

Time frame:
From the date of first study treatment until disease progression per IMWG, up to 60 months
Reported as:
Median · Months
Duration of Clinical Benefit Response (DCB)
MonthsCohort 1Cohort 2Cohort 3Cohort 4
Duration of Clinical Benefit Response (DCB)27.6 (27.6 to 27.6)3.7 (3.7 to 3.7)—11.5 (2.8 to 46.3)
SecondaryDuration of Response (DOR)

The time interval between the date of initial documentation of a response and the date of first documented evidence of progressive disease, death, or date of censoring for the subjects not progressed/died. The censoring date is the last adequate tumor assessment date.

Time frame:
up to 3 Years
Reported as:
Median · Month
Duration of Response (DOR)
MonthPCI-32765 420 mg Per DayPCI-32765 560 mg Per Day, 40 mg DexamethasonePCI-32765 840 mg Per DayPCI-32765 840 mg Per Day, 40 mg Dexamethasone
Duration of Response (DOR)—3.7 (3.7 to 3.7)—15.4 (3.6 to 27.2)

Adverse events

Collected over Five Years. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 12/13 (15.4%)6/13 (46.2%)12/13 (92.3%)
Cohort 21/18 (5.6%)6/18 (33.3%)18/18 (100%)
Cohort 31/18 (5.6%)7/18 (38.9%)17/18 (94.4%)
Cohort 41/43 (2.3%)12/43 (27.9%)43/43 (100%)
Most frequent serious events
Showing 10 of 47
Most frequent serious events
EventCohort 1Cohort 2Cohort 3Cohort 4
PneumoniaInfections and infestations1/130/181/184/43
Clostridium difficile infectionInfections and infestations1/131/180/180/43
Plasma cell myelomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/131/181/180/43
SyncopeNervous system disorders1/131/180/180/43
Aspergillus InfectionInfections and infestations1/130/180/180/43
Bone LesionMusculoskeletal and connective tissue disorders1/130/180/180/43
Bone PainMusculoskeletal and connective tissue disorders1/130/180/180/43
Device Related InfectionInfections and infestations1/130/180/180/43
Herpes Zoster DisseminatedInfections and infestations1/130/180/180/43
HyperglycaemiaMetabolism and nutrition disorders1/130/180/180/43
Most frequent other events
Showing 10 of 367
Most frequent other events
EventCohort 1Cohort 2Cohort 3Cohort 4
DiarrhoeaGastrointestinal disorders5/138/1810/1826/43
FatigueGeneral disorders3/137/189/1821/43
NauseaGastrointestinal disorders6/135/187/1811/43
Upper Respiratory Tract InfectionInfections and infestations3/132/187/188/43
ThrombocytopeniaBlood and lymphatic system disorders5/135/184/189/43
AnemiaBlood and lymphatic system disorders4/136/186/1812/43
Muscle SpasmsMusculoskeletal and connective tissue disorders4/136/183/1810/43
CoughRespiratory, thoracic and mediastinal disorders4/133/182/1812/43
PyrexiaGeneral disorders4/131/183/187/43
InsomniaPsychiatric disorders1/135/181/1813/43

Baseline characteristics

Age, Continuous
Age, Continuous(years)Cohort 1Cohort 2Cohort 3Cohort 4Total
Median62.0 ± 7.5765.5 ± 8.4465.5 ± 7.5265.0 ± 7.4065.0 ± 7.63
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1Cohort 2Cohort 3Cohort 4Total
Female5951736
Male89132656
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1Cohort 2Cohort 3Cohort 4Total
Hispanic or Latino00167
Not Hispanic or Latino1318173482
Unknown or Not Reported00033
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1Cohort 2Cohort 3Cohort 4Total
Other Race — American Indian or Alaska Native00000
Other Race — Asian00101
Other Race — Native Hawaiian or Other Pacific Islander00000
Other Race — Black or African American264618
Other Race — White1012123367
Other Race — More than one race00101
Other Race — Unknown or Not Reported10045
Region of Enrollment
Region of Enrollment(participants)Cohort 1Cohort 2Cohort 3Cohort 4Total
United States1318184392
08

Study locations

11 sites
  • SITE-13
    La Jolla, California 92093, United States
  • SITE-5
    Baltimore, Maryland 21287, United States
  • SITE-4
    Boston, Massachusetts 02215, United States
  • SITE-8
    Ann Arbor, Michigan 48109, United States
  • SITE-2
    Saint Louis, Missouri 63110, United States
  • SITE-6
    Hackensack, New Jersey 07601, United States
  • SITE-10
    New York, New York 10029, United States
  • SITE-3
    New York, New York 10065, United States
  • SITE-1
    Nashville, Tennessee 37203, United States
  • SITE-11
    Dallas, Texas 75390, United States
  • SITE-9
    Seattle, Washington 98109, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2012 to primary completion in Aug 2018, 77 months.

Of 93 industry-sponsored phase 2 interventional studies under Multiple Myeloma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 77. This study's 77 months is above that.

Counting every sponsor, half of 504 studies reached it within 57 months; a quarter within 35 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2011
First posted
Nov 23, 2011
StartActual
Mar 2012
Primary completionActual
Aug 2018
CompletionActual
Aug 2018
Results first posted
Jun 26, 2018
Last update
Mar 10, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01478581
Lead sponsor
Pharmacyclics LLC.
Responsible party
Sponsor
First posted
Nov 23, 2011
Start date
Mar 2012
Primary completion
Aug 2018
Completion
Aug 2018
Results posted
Jun 26, 2018
Last update
Mar 10, 2020

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibrutinib

Start the discussion